Are Pharmaceutical Company Payments Incentivising Malpractice in Japanese Physicians? by Kobashi, Yurie et al.
Are Pharmaceutical Company Payments Incentivising 
Malpractice in Japanese Physicians?
Yurie Kobashi1,2* ID , Makoto Watanabe3, Hideaki Kimura3, Asaka Higuchi1, Akihiko Ozaki1,4 
Letter to Editor
Full list of authors’ affiliations is available at the end of the article.
http://ijhpm.com
Int J Health Policy Manag 2019, 8(10), 627–628 doi 10.15171/ijhpm.2019.60
*Correspondence to: Yurie Kobashi, Email: tenten.yurie@gmail.com
Copyright: © 2019 The Author(s); Published by Kerman University of Medical 
Sciences. This is an open-access article distributed under the terms of the 
Creative Commons Attribution License (http://creativecommons.org/licenses/
by/4.0), which permits unrestricted use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Citation: Kobashi Y, Watanabe M, Kimura H, Higuchi A, Ozaki A. 
Are Pharmaceutical Company Payments Incentivising Malpractice in 
Japanese Physicians? Int J Health Policy Manag. 2019;8(10):627–628. 
doi:10.15171/ijhpm.2019.60
Received: 17 April 2019; Accepted: 13 July 2019; ePublished: 24 July 2019
Dear Editor,
Pharmaceutical industry (Pharma) funding plays a pivotal 
role in medical progress but has resulted in the extensive 
commercialization of clinical and academic research.1 Profit-
driven interest from Pharma has been demonstrated to have 
a negative impact on the integrity and objectivity of science, 
research publications and patient management.2,3 Pharma 
is generally held in very low esteem, especially in wealthier 
nations, with widespread claims of secrecy and bribery 
and corruption in a relentless pursuit of profits. There is a 
perceived non-disclosure of data, particularly from clinical 
trials, plus the marketing focus of Pharma companies is seen as 
compromising medical education and improperly influencing 
prescription practices. Pharma spends on about twice as much 
on marketing as on research and development of new drugs. 
Furthermore, much ‘research’ is disguised as science whereas 
it is actually for marketing purposes. Scientists, physicians 
and regulators are tainted by being recognized as complicit in 
these activities. 
In 2004, the World Medical Association proclaimed that 
conflicts of interest between Pharma and physicians can 
adversely affect patient care as well as the reputation of the 
medical profession. Physicians are supposed to objectively 
decide what is best for the patient, while Pharma aims for 
financial profit for their shareholders by selling their own 
products and out-competing rivals. Commercial incentives 
can thus jeopardise a physician’s objectivity. However, instead 
of prohibiting relationships between physicians and Pharma, 
the World Medical Association advises establishing self-
policing guidelines to govern such relationships. These must 
encompass the key principles of disclosure, avoidance of 
obvious conflicts of interest, and safeguarding the physician’s 
autonomy to act in the best interests of their patients. 
Physician/Pharma interactions and acceptance of gifts 
from a company are known to affect physicians’ prescribing 
behavior and contribute to irrational prescribing of the 
company’s products.4 Thus, it is imperative to encourage 
complete transparency in Pharma/physician relationships. 
The Physician Payments Sunshine Act, enacted in the United 
States in 2010, marked a first step toward accomplishing this. 
And since 2014, the government’s Center for Medicare and 
Medicaid Services has been reporting payment information 
to healthcare providers and educational hospitals on the Open 
Payment website (https://www.cms.gov/openpayments/), to 
which the general public has unlimited access. Furthermore, 
the American Medical Association has repeatedly and 
extensively stressed the necessity for transparency in financial 
relationships between Pharma companies and physicians.5
In Japan, steps are also being taken to rectify the problem. 
The Japan Pharmaceutical Manufacturers Associations 
(JPMA) created the ‘Transparency Guideline for the Relation 
between Corporate Activities and Medical Institutions’ 
in 2011. This requires the 78 pharmaceutical companies 
belonging to the JPMA to disclose details of all their 
payments to healthcare providers, together with their names 
and affiliations. Each company should itemize their payment 
details on its own website, in a timely fashion, with open 
access. Unfortunately, formats for the data have not been 
specified, there is no uniformity, and so much is unclear 
and not easily comparable. Thus, it has not been possible 
for researchers, journalists or the public to obtain or analyze 
data easily. The JPMA’s latest 2018 guideline update has not 
improved things in this respect. This is surprising given that 
the JPMA experienced infamous scientific misconduct with 
the Valsartan Scandal, in which an employee of Novartis was 
deeply involved in data fabrication in multiple clinical trials, 
leading to the retraction of all main academic articles on the 
drug.6 Similarly, healthcare providers have not actively sought 
to change their relationships with Pharma, possibly because a 
majority of high-ranking physicians, such as medical school 
professors, have been benefitting substantial from the cozy 
financial relationships.
To provide increased transparency, we have created a 
uniform database of Pharma payments to physicians in Japan, 
using the payment data disclosed on 78 Pharma company 
websites. A comprehensive analysis of the payment data with 
respect to Executive Board members of Professional Medical 
Associations,7 Clinical Practice Guidelines authors,8 and 
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researchers involved in the Valsartan Scandal,6 revealed their 
significant financial support from Pharma. The database has 
been available to all on the Money Database website (http://
db.wasedachronicle.org/) since January 15, 2019. So far, it 
has attracted more than 2 500 000 page views, engendering 
significant media coverage. While it is too soon to know 
whether or not the initiative has enhanced the health and 
well-being of patients, or whether it is possible to measure 
this, the new database has certainly helped raise awareness of 
this controversial issue among the general population.
It is clear that Pharma has a herculean task to rebuild trust, in 
Japan, the United States and in many other parts of the world, 
mostly in the wealthier nations. An extensive global survey in 
2018 found that only 55% of people trusted Pharma, a figure 
which had remained constant for a decade [Edelman Trust 
Barometer 2018. https://www.edelman.com/sites/g/files/
aatuss191/files/2018-10/Edelman_Trust_Barometer_Global_
Healthcare_2018.pdf]. In the United States, unacceptably 
high drug prices, the opioid scandal, class-action cases against 
perceived Pharma wrongdoings, and other factors are actually 
threatening the actual existence of several Pharma companies. 
Despite the 2010 Physician Payments Sunshine Act and other 
initiatives, US public trust in Pharma fell from 51% in 2017 
to 38% in 2018, condemning the industry to the “distrusted” 
category. In Japan, trust in Pharma among the general public 
had risen 14 points to 68% in the same timeframe.
Despite the obvious potential ethical violations in Pharma/
physician linkages, it is unlikely that the new Japanese 
database will have much impact on changing them, as the 
JPMA guidelines are not mandatory or enforced, and there 
are no penalties involved for non-compliance. The JPMA’s 
position is “we hope that the medical institutions and medical 
professionals will kindly understand the purpose of this 
Guideline and provide their cooperation.” Moreover, Pharma 
companies outside the JPMA are not involved in the data 
sharing. There is a need to enact rigorous legislation to prevent 
Pharma from using their power and funding to influence the 
activities of physicians for their own benefits.
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